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Abstract
Background: While most Sub-Saharan African countries are now implementing the WHO-recommended Option B+
protocol for prevention of vertical HIV transmission, there is a lack of knowledge regarding the influence of Option B+
exposure on adverse birth outcomes (ABOs). Against this background, we assessed ABOs among delivering women in
Western Uganda.
Methods: A cross-sectional, observational study was performed within a cohort of 412 mother-newborn-pairs in Virika
Hospital, Fort Portal in 2013. The occurrence of stillbirth, pre-term delivery, and small size for gestational age (SGA) was
analysed, looking for influencing factors related to HIV-status, antiretroviral drug exposure and duration, and other
sociodemographic and clinical parameters.
Results: Among 302 HIV-negative and 110 HIV-positive women, ABOs occurred in 40.5%, with stillbirth in 6.3%, pre-term
delivery in 28.6%, and SGA in 12.2% of deliveries. For Option B+ intake (n= 59), no significant association was found with
stillbirth (OR 0.48, p= 0.55), pre-term delivery (OR 0.97, p= 0.92) and SGA (OR 1.5, p= 0.3) compared to seronegative
women. Women enrolled on antiretroviral therapy (ART) before conception (n= 38) had no different risk for ABOs than
women on Option B+ or HIV-negative women. Identified risk factors for stillbirth included lack of formal education, poor
socio-economic status, long travel distance, hypertension and anaemia. Pre-term delivery risk was increased with poor
socio-economic status, primiparity, Malaria and anaemia. The occurrence of SGA was influenced by older age and Malaria.
Conclusion: In our study, women on Option B+ showed no difference in ABOs compared to HIV-negative women and to
women on ART. We identified several non-HIV/ART-related influencing factors, suggesting an urgent need for improving
early risk assessment mechanisms in antenatal care through better screening and triage systems. Our results are encouraging
with regard to continued universal scale-up of Option B+ and ART programmes.
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Background
Maternal HIV infection can increase the occurrence of
adverse birth outcomes (ABOs), such as pre- term deliv-
ery (PTD), stillbirth (SB), or newborns too small for ges-
tational age (SGA) [1–3]. Not only HIV infection itself,
but also HIV- associated conditions like lower maternal
body weight, anaemia, sexually transmitted infections,
Malaria, or Tuberculosis [4–7] are associated with
higher rates of ABO. Prophylactic antiretroviral (ARV)
drug regimens during pregnancy are not only an
instrument for prevention of mother-to-child-transmis-
sion of HIV (PMTCT), but can also improve the
mother’s health and positively influence conditions
associated with ABO occurrence [8]. Since 2012, the
WHO has recommended “Option B+” for PMTCT [9],
which stands for initiation of life-long antiretroviral ther-
apy (ART) among all HIV- positive pregnant women.
This approach has since then been further strengthened
by the trend to lower thresholds for ART initiation,
particularly by the recent WHO release of “treat all”- rec-
ommendations, pursuing ART for all HIV-positive individ-
uals including pregnant women. Consequently, the vast
majority of PMTCT clients in the near future will be
exposed to lifelong ART [8].
However, ARV drugs themselves may also negatively
influence the occurrence of ABOs, and thus increase
perinatal morbidity and mortality. Research has shown
higher rates for SB [10, 11], PTD [12–15] and SGA [11,
16, 17] for infants of women who take ARVs for treat-
ment or prevention. SGA and PTD do not only have an
immediate influence on perinatal mortality, but have re-
percussions on the under-1-year and even under-five
year infant morbidity and mortality [18, 19]. While it
seems that ARV regimens containing protease inhibitors
(PI) have a higher influence on the occurrence of ABOs
[17, 20–23], possible relations were also discovered for
Nucleotide/Nucleoside reverse transcriptase inhibiting
(N(t)RTI) and non- NRTI (NNRTI) drugs now recom-
mended as Option B+ regimen [10, 12–14]. There also
seems to be an association between ABOs and the dur-
ation of drug intake and time of drug initiation, with
pre-conception drug intake linked with higher odds for
ABOs than initiation during pregnancy [10, 24, 25].
HIV serostatus and different ARV drug regimens for
HIV seropositive women may thus both negatively influ-
ence birth outcome. Increasing numbers of women and
infants will benefit from the therapeutic and preventive
effects of ARV intake during pregnancy. In this light,
more information about possible adverse effects of ARV
exposure is required. Since ABOs have substantial
impact on the overall morbidity and mortality of infants,
we aimed to understand their association with different
types and duration of ARV exposure (ART or Option B
+) in pregnancy.
In Uganda, an estimated 1.6 million people are living
with HIV/AIDS, of which around 170 thousand are chil-
dren [26]. While the nation-wide prevalence of HIV in
pregnant women is 6.1% [27], the prevalence of 13.4% in
Kabarole district, Western Uganda, is among the highest
in the country [28]. The total fertility rate of Ugandan
women is 6.0 children. The neonatal mortality rate is es-
timated at 23/1000, and the SB rate at 25/1000 births.
Low birth weight incidence was 14% in 2011 [29]. As of
2011, 57.4% of women delivered in a health facility [29].
The implementation of Option B+ in Uganda for
PMTCT started at the end of 2012. Our study aimed at
assessing ABOs among women and their newborns in
Fort Portal, Uganda, under consideration of ARV expos-
ure during pregnancy.
Methods
We conducted a cross-sectional study to investigate the
occurrence of birth outcomes like SB, PTD and SGA
among a cohort of delivering women in Fort Portal,
Uganda. The primary objective was to assess possible
influence of HIV serostatus and ARV exposure duration
and type (ART or Option B+). Furthermore, we assessed
associations of non-HIV related factors to the occur-
rence of ABO.
Study site
Virika Hospital, a private catholic hospital representing
one of two referral hospitals of Kabarole District, offers
standard antenatal, delivery and HIV care and contains a
32-bed obstetric department. Around 10% of delivering
women are HIV-infected in this setting. For women
identified HIV-positive during pregnancy, Option B+ for
PMTCT is applied since September 2012. For assumed
seronegative delivering women, HIV status is reassessed
peripartumly as a routine procedure. In accordance with
the Ugandan PMTCT protocol, all tested women receive
pre- and post-test counselling, and those who test posi-
tive are counselled and immediately enrolled in Option
B+ drug regimen. All women receive adequate standard
obstetrical care.
Data collection
From February until December 2013, women who came
to Virika Hospital for delivery were recruited into the
study. Eligibility criteria included age 18 years or older,
singleton pregnancy, informed written consent, and
known HIV serostatus (as confirmed in routine peripar-
tum testing). Upon recruitment, we obtained socio-
demographic, obstetric, and medical data by using an
interviewer-administered, structured questionnaire based
on women’s self-report. Medical data involved history of
Malaria infection and HIV-related data, which included
prophylactic and therapeutic measures during the
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current and former pregnancies. Women were examined
clinically and obstetrically, and a venous blood sample
was taken. Malaria status at delivery was determined by
microscopy and a rapid test device. Haemoglobin (HB)
level was determined using photometer technique. The
newborn’ s birth outcome and weight were documented.
Gestational age in weeks (GW) of the newborns was
assessed using the Finnstroem scoring system [30].
The outcome variables were defined as follows: SB was
determined as a newborn above 28 GW, delivered with
an APGAR score of 0 in the first and after five minutes.
PTD was specified as a newborn with an equivalent
score of 37 GW or less according to the Finnstroem
score assessment. We defined infants to be SGA if they
had a birth weight below the 10th percentile of a foetal
growth chart. Since to date no growth chart is available
for Uganda, we used a chart developed for Tanzania
[31]. Due to cultural reasons, stillborn infants were often
taken away by the family before they could be assessed
and weighed. Some SB babies were therefore missing in
the PTD and SGA analysis, but all were included in the
SB analysis.
The explanatory variable “HIV-negative” was defined
as having had a negative bedside peripartum test; “ART
pre-conception” (ARTpc) was specified as having com-
menced a highly active ARV treatment (Tenofovir, Lami-
vudine and Efavirenz as recommended first-line
regimen) before conception of the current pregnancy.
The definition of “Option B+” was the intake of the
ARV combination Tenofovir, Lamivudine and Efavirenz,
initiated during the current pregnancy. Date of treat-
ment/PMTCT start was extracted from the ANC card,
or self- reported if ANC card was missing.
Since it was shown that a protective effect of
PMTCT due to viral load reduction requires a mini-
mum of 90 days of ARV intake [32–34], we used this
as cut-off point for analysing influence of ARV intake
duration before delivery. A second cut-off point was
set at 14 GW, as ARV exposure early in pregnancy is
particularly suspected to influence ABO occurrence
[10, 12, 24, 35, 36].
Six women referred from external facilities were still
enrolled on the “Option A” regimen (Zidovudine after
GW 14 and Co-trimoxazole) at the time of delivery. For
two women, the PMTCT regimen was not specified.
These were included in analyses concerning serostatus
and non- HIV related explanatory factors for ABO, but
excluded from ARV-related analysis. All women on
Option A were changed on Option B+ regimen after de-
livery and referred to chronic HIV care. Only five HIV-
positive women were not on ARVs, with two of them
not being aware of their seropositivity. They were
included in descriptive baseline analysis, but excluded
from analysis of HIV/ARV related parameters.
As non-HIV related explanatory variables for ABO,
haemoglobin level of 11.5 g/dl and less was defined as
anaemia, using the WHO definition of 11 g/dl, adding
0.5 g/dl to adjust for the study site’s altitude of 1550 m
[37]. The occurrence and gestational week of Malaria in
pregnancy (MIP) were either extracted from the ANC
card or self- reported by the women. Where the last nor-
mal menstrual period date was available, MIP was classi-
fied as having occurred in the first trimester, or after
start of the second trimester. Women whose laboratory
examination confirmed Malaria infection upon delivery
were included into the variable “Malaria within two
weeks prior delivery”. The variable “any obstetric risk
history” consisted of self-reported obstetric history of
abortion, stillbirth, preterm delivery and preterm labour
and clinical findings during this current pregnancy, in-
cluding hypertension, pre-eclampsia, or sexually trans-
mitted diseases.
Socio-economic status (SES) was classified by using a
scale of self-reported availability of resources in the
woman’s household as proxies, such as tap water, electri-
city, refrigerator, motorbike/car, cattle, cupboard, and
television. Lowest SES was defined as having none of the
proxy assets available in the household. We also assessed
whether the women benefitted from transport and deliv-
ery cost coverage through support organisations (e.g.,
Baylor Uganda).
Data analysis
Data was entered into Excel (Microsoft) data sheets and
checked for consistency. Data analysis was carried out
using IBM SPSS Statistics, version 22.0. We performed
descriptive analysis of the sociodemographic, economic
and clinical background of clients and tested for differ-
ences between HIV-positive and negative women. Clin-
ical outcomes of newborns were described and equally
tested for differences according to HIV-exposure. For
univariate analysis, Mann- Whitney or Kruskal-Wallis
test was used for continuous data, and Pearson’s Chi
Square and Fisher’s exact test (as appropriate) for cat-
egorical data. We looked for factors influencing the out-
come variables SB, PTD, SGA calculating odds ratios
(OR). Explanatory variables which were significant in
univariate analysis were included into multivariate logis-
tic regression to calculate adjusted odds ratios (AOR). A
significant p-value ≤0.05 and a confidence interval of
95% was used for all analyses.
Results
Socio-demographic characteristics
From 912 deliveries in the recruitment period, 412
mother-newborn-pairs fulfilled eligibility criteria for
inclusion into the study; 445 (48.8%) had to be excluded
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from the cohort because of missing peripartum serostatus
determination, 55 due to other non- eligibility criteria.
Within our cohort 302 women were confirmed seronega-
tive, and 110 were confirmed seropositive. Among HIV-
positive women, 38 (34.5%) had already been on ART be-
fore conception, and 59 (53.6%) were enrolled in the
Option B+ PMTCT programme (five women untreated,
eight women on other PMTCT regimens). Of the women
taking ARTpc or Option B+, 81 (84.4%) commenced drug
intake a minimum of 90 days before delivery, while 15
(15.6%) received Option B+ for less than 90 days (one miss-
ing data on intake duration). The median intake of Option
B+ was 131 days prior to delivery. The five untreated sero-
positive participants showed no clinical signs of advanced
disease, anaemia was documented in two cases.
Basic sociodemographic data are shown in Table 1.
Participants were most frequently from Kabarole district
and Batooro ethnicity. Travel distance to Virika Hospital
was on average 60 min. While 168 (41.1%) women were
referred for deliveries from lower level healthcare ser-
vices, free of charge transport and delivery cost coverage
was provided for 72 (18.7%). Almost all women (97.5%)
had presented at least once to ANC services, with an
average of 4 visits during the pregnancy. The majority
(90.4%) of women had received Malaria prophylaxis.
HIV-infected women were significantly less often in a
partner relationship compared to non-infected women
(p = 0.005). The risk of HIV infection was negatively cor-
related with school education on a significant level (p =
0.021), and increased with parity (p = 0.008), and, by
trend, with age (p = 0.052).
Obstetric and newborn data
Of the 412 women, 32.4% were primiparae, and 11.7%
grand multiparae (five or more deliveries). According to
their clinical history, 30.4% of women had an obstetric
risk or pathologies within the current pregnancy. HIV-
positive women showed increased odds for having an
obstetric risk history, especially for previous SB (OR 2.5,
CI 1.09–5.77, p = 0.027) or preterm labour (OR 5.66 CI
1.02–31.34, p = 0.046). 27.4% reported MIP, of which
15.8% occurred within the 3rd trimester, and 6.1% within
the last 2 weeks prior to delivery. A positive peripartum
bedside Malaria test was found in 13 (3.4%) cases. Aver-
age haemoglobin level was 12.23 g/dl (SD 1.98), anaemia
was found in 117 (31.4%) of women at delivery.
In our study cohort, 209 male and 201 female single-
tons were delivered (sex not reported in two cases).
Birth weight was significantly lower for female infants
(p= 0.01). 157 newborns were delivered by caesarean
Table 1 Sociodemographic and clinical baseline data, difference by HIV status
Variables Overall HIV negative HIV positive ORa CI 95% P valueb
N total (%) 412 (100) 302 (73.3) 110 (26.7)
Age (years)c 25 (18–42) 25 (18–42) 26 (18–42) 0.052d
No. of persons in householdc 4 (1–22) 4 (1–22) 3.5 (1–10) 0.08d
Single/widowed/divorced e 67/410 (16.3) 40 (13.3) 27 (24.8) 2.15 1.24–3.72 0.005
Education: primary and lesse 242/405 (59.8) 168 (56.4) 74 (69.2) 1.74 1.09–2.78 0.021
Income generating activitye 101/394 (25.6) 69 (24.0) 32 (30.2) 1.37 0.84–2.25 0.21
Socioeconomic status: lowest categorye 92/411 (22.4) 74 (24.6) 18 (16.4) 0.6 0.34–1.06 0.08
Travel distance to hospital ≥90 mine 74/374 (19.8) 61 (21.8) 13 (13.8) 0.58 0.3–1.11 0.094
Referral from other health facilityle 168/409 (41.1) 123 (41.1) 45 (40.9) 0.99 0.64–1.55 0.97
Cost coverage grant for transport/deliverye 103/397 (25.9) 60 (20.3) 43 (42.2) 2.9 1.76–4.63 <0.001
Primiparitye 131/409 (32.4) 107 (35.5) 24 (21.8) 0.51 0.3–0.84 0.008
Grand multiparity (≥5 deliveries)e 48/411 (11.7) 35 (11.6) 13 (11.8) 1.02 0.52–2.01 0.96
Any obstetric risk historye 122/401 (30.4) 71 (24.1) 51 (48.1) 2.93 1.84–4.66 <0.001
Hypertensione 10/412 (2.4) 8 (2.6) 2 (1.8) 0.68 0.14–3.26 0.63
MIP reportede 110/402 (27.4) 84 (28.3) 26 (24.8) 0.84 0.5–1.39 0.49
Anaemia ≤11.5 mg/dle 117/373 (31.4) 84 (29.9) 33 (35.9) 1.31 0.8–2.2 0.28
ANC attendance: yese 387/397 (97.5) 286 (97.6) 101 (97.1) 0.82 0.21–3.25 0.78
No. of ANC visitsc 4 (0–9) 4 (0–9) 4 (0–9) 0.16d
aAll dichotomous variables consist of the respective attribute compared to the converse attribute and were cross tabulated against the women’s serostatus. The
results of the converse attribute is not displayed
bBivariate, Pearson’s X2 asymptotic two-sided p-value, if not indicated otherwise. P-values in italics indicate statistically significant differences between the groups
cmedian (range)
dMann–Whitney-U-Test
en/total n with available data (%)
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section (38.6%), four (1%) by obstetric operative methods
and 246 (60.4%) as spontaneous vaginal delivery (5 miss-
ing data). Basic infant data differentiated for maternal
HIV serostatus is shown in Table 2.
Adverse birth outcomes
ABOs were observed in 165 (40.3%) of women (n= 409, 3
missing data for SGA), with no significant difference (p =
0.57) between male (n = 86, 41.5%) and female (n = 78,
39%) newborns. ABOs occurred in 119 (39.7%) of sero-
negative and 46 (42.2%) of seropositive women (p = 0.64).
The difference in occurrence of SB (OR 0.81, p = 0.67),
PTD (OR 1.01, p = 0.97) and SGA (OR 1.18, p = 0.63) was
not significant according to serostatus (Table 3).
There was also no difference in the occurrence of ABOs
between the groups of exposure to ARVs. Among the 5
HIV-positive unexposed women, there was no ABO re-
ported apart from one woman, who had anaemia and
PTD at 37 GW. Compared to seronegative women,
women on ARTpc did not have a significantly elevated
risk for ABO occurrence (OR 0.82, CI 0.4–1.68, p = 0.59).
The same was found for women on Option B+ (OR 1.2,
CI 0.68–2.11, p = 0.53). When comparing the two groups
of ARV exposure, ARTpc and Option B+, to each other,
there was also no significance (OR 1.46, CI 0.62-3.4, p =
0.39) in ABO risk difference. No differing ABO risk could
be reported for women who took ARV drugs longer or
shorter than 90 days (OR 0.55, CI 0.18–1.68, p = 0.29) as
well as among ARV-exposed and HIV-negative women
during first trimester (OR 0.82, CI 0.36–1.87, p = 0.64).
Stillbirth
In our cohort, 26/412 (6.3%) mothers delivered a still-
born infant. Women who had no formal education, were
of poor SES, had hypertension, and who had anaemia
were more likely to experience SB. SB occurred also
more often to women who were referred to Virika
Hospital from a distance of more than 90 min of travel
time. In multivariate logistic regression, hypertension in
pregnancy (AOR 18.03, CI 3.31–98.1, p = 0.001) and a
travel distance to Virika Hospital of > 90 min (AOR 5.83,
CI 2.21–15.42, p < 0.001) remained highly significant risk
factors for SB (Table 4).
Pre-term delivery
In 116 of 410 deliveries (missing gestational age in two
cases), newborns were born pre-term (28.3%). PTD was
more frequent in women of poor SES, lower education,
primiparity, MIP in the last 2 weeks before delivery and
anaemia (Table 5). Blood haemoglobin was on average
11.9 g/dl (5.9–15.9 g/dl, SD 1.87). Protective factors
against PTD were tertiary education (OR 0.39, CI
0.16–0.96, p = 0.034), and higher SES (OR 0.47, CI
0.25–0.88, p = 0.008). After logistic regression, only an-
aemia (AOR 1.69, CI 1.01–2.84, p = 0.047) and MIP
within the last 2 weeks before delivery (AOR 2.58, CI
1.03–6.46, p = 0.044) remained risk factors for PTD.
Small for gestational age
Of 399 newborns with documented gestational duration
and birth weight, 47 (11.8%) were SGA (Table 6). Com-
paring SGA occurrence among women with ARV intake
>90 days to HIV-negative, ARV unexposed women, SGA
risk was not different (Table 2). No significant correla-
tions were found when assessing marital status, occupa-
tion, obstetric risk history, or haemoglobin level
(Median 12.6 g/dl, SD 1.86, p = 0.89) for risk of SGA. In
univariate analysis, women over the age of 30 years were
more prone to deliver an SGA infant. If women experi-
enced MIP, those with an SGA baby had the episode
Table 2 Basic Infant data
Variables Overallla No HIV exposure N (%) HIV exposure N (%) OR CI 95% P valueb
N total 412 302 110
Gestational week (Finnstroem score)c 38 (28–42) 39 (28–42) 38 (30–42) 0.5d
Birth weightc 3095 (500–4500) 3100 (500–4500) 3040 (1200–4500) 0.821d
APGAR scorec 10 (0–10) 10 (0–10) 10 (0–10) 0.34d
Newborn sex
Male 209/410 (51.0) 156 (52.0) 53 (48.2) 1
Female 201/410 (49.0) 144 (48.0) 57 (51.8) 1.17 0.75–1.8 0.49
Stillbirth 26/412 (6.3) 20 (6.6) 6 (5.5) 0.81 0.32–2.08 0.67
Preterm delivery 116/410 (28.3) 85 (28.2) 31 (28.4) 1.01 0.62–1.64 0.97
Small for gestational age 47/399 (11.8) 33 (11.3) 14 (13.1) 1.18 0.61–2.31 0.63
Any adverse birth outcome 165/409 (40.3) 119 (39.7) 46 (42.2) 1.11 0.71–1.73 0.64
aAll data n/total n with available respective data (%), if not indicated otherwise
bBivariate, Pearson’s X2 asymptotic two- sided p- value
cMedian (range)
dMann–Whitney-U-Tes
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significantly later in pregnancy (Median 34.0 GW versus
28 GW, p = 0.02). After logistic regression, MIP in the
third trimester was still a significant risk factor for SGA
(Table 6).
Discussion
This cross-sectional, observational study assessed the oc-
currence of ABOs and their associations with maternal
HIV status, ARV exposure and other influencing factors
in a Western Ugandan health facility. PMTCT- Option B
+ had recently been introduced here, and this is the first
study to investigate possible associations between ABOs
and Option B+ in this region.
In our cohort, the overall rate of ABOs was alarmingly
high, and only few other studies, albeit also conducted
in referral institutions, have reported similarly high rates
[38–41].
Maternal ARV intake and maternal HIV infection have
both been known to be potential risk factors for ABOs.
While increased ABO risk is frequently reported for
seropositive untreated women compared to HIV-
negative women [42–44], we did not find a significant
difference among seropositive women receiving ARVs
and seronegative women. These results are in line with
other publications [17, 39, 45–49]. The majority of
HIV-positive women in our study had reported ARV
Table 4 Adverse birth outcome: Stillbirth (SB)
Variables SBa,b OR CI 95% P- valuec AOR CI 95% P- value
N Total 26
Age 26
<30 year 19 (6.2) 1
≥30 year 7 (6.7) 1.08 0.44–2.65 0.86
Education 26
Primary and higher 21 (5.5) 1
No formal education 5 (21.7) 4.78 1.62–14.12 0.011d 1.12 0.22–5.67 0.89
Occupation 26
Income generation 5 (5.0) 1
No income generation 21 (7.2) 1.48 0.54–4.04 0.44
Socioeconomic status (SES) 26
Higher SES (≥1 assets) 15 (4.7) 1
Lowest SES (0 assets) 11 (12.0) 2.75 1.22–6.22 0.012 1.89 0.69–5.17 0.21
Parity 26
Primiparity 7 (5.3) 1
Multiparity (≥2 deliveries) 19 (6.8) 1.29 0.53–3.15 0.58
Travel distance 24
<90 min 11 (3.7) 1
≥90 min 13 (17.6) 5.6 2.4–13.1 <0.001d 5.83 2.21–15.42 <0.001
Hypertension 26
No hypertension 22 (5.5) 1
Hypertension 4 (40) 11.52 3.03–43.81 0.002 18.03 3.31–98.1 0.001
Malaria in pregnancy 26
No MIP detected peri-partum 24 (6.4) 1
MIP detected peri-partum 2 (15.4) 2.64 0.55–12.61 0.22d
MIP >3rd trimester 3 (4.6) 1
MIP ≤2nd trimester or no MIP 23 (6.6) 1.47 0.43–5.04 0.78d
Anaemia ≤11.5 mg/l 24
No 12 (4.7) 1
Yes 12 (10.3) 2.32 1.01–5.34 0.042 2.26 0.88–5.84 0.09
aAll data N (%)
bPercentages refer to the number of participants with available data on respective variable
cBivariate, Pearson’s X2 asymptotic two-sided p-value if not indicated otherwise. P-values in italics indicate statistically significant differences between the groups
dBivariate, Fisher’s Exact test two- sided p- value
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exposure (ART or Option B+) exceeding 90 days, with
presumably favourable effect on viral load and immuno-
logic response by the time of delivery. Hence, our find-
ings suggest a levelling-out effect of ARVs with respect
to HIV infection as a risk factor for ABOs.
Among HIV-positive study participants, having started
drug intake before conception (ARTpc) did not lead to a
difference in ABO risk compared to having started only
in pregnancy (Option B+). This is in accordance with
findings from other studies, e.g. regarding PTD [22, 50]
and SGA [17, 21, 48, 49]. For SB, our finding contradicts
previous research, where higher risk for SB was reported
among ARV-exposed women when intake started prior
conception or early in pregnancy [11–13, 24, 40]. How-
ever, Cotter et al. [17] also did not observe risk differ-
ences for SB in relation to pre-conception ARV
exposure. Among those initiating drug intake during
pregnancy, length of Option B+ intake prior delivery did
not play a significant role in our cohort.
In line with other studies, no difference was found for
SGA risk among women taking ARV drugs and their
seronegative counterparts. Several studies observed in-
creased risks for PTD for women exposed to ARTpc
containing PIs, probably caused by altered maternal pro-
gesterone levels [21, 24, 51, 52]. In our observational set-
ting, apart from one woman, none took a regimen
comprising PIs. The exposure to ARV combinations
used in this study (N(t)RTIs and NNRTIS) did not have
an increased risk for PTD and SB when compared to
HIV-negative women, even if taken very early or
throughout pregnancy. This confirms the result of other
studies [17, 20, 34, 40, 53, 54]. At the same time, Mar-
azzi et al. [34] could show a dramatic decrease of SB rate
in women on ARV therapy compared to non-treated
Table 5 Adverse birth outcome: Pre- term delivery (PTD)
Variables PTDa,b OR CI 95% P-valuec AOR CI 95% P- value
N total 116
Age 116
<30 year 84 (27.5) 1
≥30 year 32 (30.8) 1.18 0.72–1.91 0.52
Education 114
Tertiary 6 (14.3) 1
Secondary and less 108 (29.8) 2.55 1.04–6.23 0.034 1.67 0.63–4.4 0.3
Socioeconomic status (SES) 115
Higher SES (≥1 assets) 79 (24.9) 1
Lowest SES (0 assets) 36 (39.1) 1.94 1.19–3.16 0.008 1.48 0.72–3.06 0.29
ANC attendance 111
Yes 106 (27.4) 1
No 5 (62.5) 4.42 1.04–18.81 0.043d 5.42 0.88–33.54 0.07
Parity 115
Multiparity (≥2 deliveries) 68 (24.5) 1
Primiparity 47 (35.9) 1.73 1.1–2.71 0.017 1.61 0.96–2.69 0.07
Malaria in pregnancy
No MIP detected peri-partum 102 (27.5)/108 1
MIP detected peri-partum 6 (46.2) 2.26 0.74–6.89 0.2
MIP >2 weeks prior deliv. or no MIP 98 (26.1)/110 1
≤2 weeks prior delivery 12 (48.0) 2.61 1.15–5.91 0.018 2.58 1.03–6.46 0.044
MIP >3rd trimester 17 (26.2)/116 1
MIP ≤2nd trimester or no MIP 99 (28.7) 1.14 0.62–2.07 0.68
Anaemia ≤11.5 mg/l 99
No 60 (23.5) 1
Yes 39 (33.6) 1.65 1.02–2.67 0.04 1.69 1.01–2.84 0.047
aAll data N (%)
bPercentages refer to the number of participants with available data on respective variable
cBivariate, Pearson’s X2 asymptotic two-sided p- value if not indicated otherwise. P-values in italics indicate statistically significant differences between the groups
dBivariate, Fisher’s Exact test two- sided p- value
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seropositive women. Hence, the potential toxicity of
ARVs might be counterbalanced by the positive effect of
the drugs on maternal HIV infection. ART programmes
are being extensively scaled-up in most HIV-endemic
countries, and therefore constantly increasing numbers
of women in reproductive age will be enrolled in ART in
the near future, while at the same time, more and more
women will continue ART lifelong in the course of
Option B+. Therefore it is an encouraging finding that
ARV exposure does not seem to increase the risk for
ABOs, even if taken for a long time.
In our study, ABO risk was negatively correlated to
educational level and SES, a finding that has been well
described in other settings [38, 55, 56]. We identified a
number of clinical preconditions significantly linked with
ABOs. A history of ABO was a predictor for repeated
occurrence of the same event, which confirms previous
research in other similar settings [38, 39, 43, 55, 57]. An
increased risk of SB for women in our study with hyper-
tension was accordingly reported in other studies [38,
56]. We also found that primigravid women were more
prone to deliver a pre-term infant, supporting findings
from Taha et al. [58]. Maternal anaemia was strongly
correlated with SB and PTD in our study, also described
by Watson-Jones et al. and Turner [55, 59]. Even though
ANC at Virika Hospital routinely provides ferrous
sulphate and folic acid, this does not seem to be enough
to tackle the problem of anaemia. Laboratory haemoglo-
bin testing during the antenatal period could help to fil-
ter out anaemic women and treat them according to the
cause of anaemia. In general, our findings suggest that
ANC surveillance to identify women with risk parame-
ters needs to be strengthened, including assessment of
the socio-economic situation and thorough history tak-
ing. Adequate blood pressure monitoring and early treat-
ment of these women will contribute to lower the risk
for ABOs. SB occurred to many women who were
referred due to obstetrical complications. In line with
other research [56], women with higher distance to the
referral site and thus increased danger of foetal distress
experienced SB more frequently. This implies that there
is still need to improve the triage system for warning
signs of ABO at the smaller health centres. Women with
risk factors need to be referred already at ANC level, or
early after their arrival for delivery. Also, better access,
financially and transport-wise, needs to be reinforced to
Table 6 Adverse birth outcome: Small for Gestational Age (SGA)
Variables SGAa,b OR CI 95% P- valuec AOR CI 95% P- value
N total SGA 47
Age 47
≥30 year 7 (6.9) 1
<30 year 40 (13.5) 2.11 0.92–4.88 0.049 2.09 0.9–4.85 0.085
Education 47
No formal education 2 (9.1) 1
Primary and higher 45 (12.1) 1.38 0.31–6.09 1.0d
Socioeconomic status (SES) 47
Higher SES (≥1 asset) 37 (12.0) 1
Lowest SES (0 assets) 10 (11.1) 0.92 0.44–1.93 0.82
Parity 47
Grand multiparity ≥5 deliveries 2 (4.2) 1
Parity ≤4 deliveries 45 (12.7) 3.21 0.75–13.72 0.1
Malaria in pregnancy 47
MIP detected peri-partum 1 (7.7) 1
No MIP detected peri-partum 44 (12.2) 1.67 0.21–13.12 1.0d
MIP ≤2nd trimester or no MIP 34 (10.6) 1
MIP >3rd trimester 13 (20.3) 2.26 1.12–4.57 0.02 2.24 1.1–4.54 0.026
Anaemia ≤11.5 mg/l 46
Yes 13 (11.8) 1
No 31 (12.4) 1.06 0.53–2.11 0.88
aAll data N (%)
bPercentages refer to the number of participants with available data on respective variable
cBivariate, Pearson’s X2 asymptotic two-sided p- value if not indicated otherwise. P-values in italics indicate statistically significant differences between the groups
dBivariate, Fisher’s Exact test two- sided p- value
Rempis et al. BMC Pregnancy and Childbirth  (2017) 17:82 Page 9 of 12
reach women in urgent need for adequate handling of
risk pregnancies/deliveries. In our study setting, trans-
port and cost coverage were provided to a part of the
women, but these programs need to be expanded, and
further research evaluating strategies for increasing
accessibility is urgently required.
MIP turned out to be an important predictor of ABO
occurrence. There was a strong correlation between MIP
occurring later in pregnancy and SGA (3rd trimester) as
confirmed by Schmiegelow et al. [60], who found that
sonographically assessed foetal growth was altered by
MIP especially in the last trimester, even if women con-
sequently received antimalarial treatment. Rijken et al.
[61] found that a single or even asymptomatic MIP epi-
sode could cause foetal growth alteration. Landis et al.
[62] observed high rates of SGA (29%) confirmed by
ultrasound, equally linked with MIP. Similarly, we ob-
served a higher occurrence of PTD for women with MIP
within the last 2 weeks prior delivery, congruent with
findings of other authors [63, 64]. MIP remains a crucial
risk factor for ABO until late pregnancy [65, 66]. This
implies a revision of strategies to prevent MIP for all
women. Other research focussing on MIP in our study
setting found that intermittent preventive treatment in
pregnancy recommended for the region might no longer
be adequate. High resistance of Plasmodium falciparum
towards intermittent preventive treatment with sulfadox-
ine/pyrimethamine was detected, as reported in detail
elsewhere [37]. Thus, immediate action is required to
provide effective prophylaxis against MIP also with
respect to ABO reduction in this setting.
Partly explained by the nature of our observational
study setting, this research had some limitations. Since
the number of ARV-unexposed seropositive women was
very low, “HIV status” as an isolated risk factor as op-
posed to “ARV exposure” could not be assessed in this
cohort. However, since the subgroup of HIV-infected
while ARV-unexposed pregnant women will in general
gradually disappear thanks to the universal scale-up of
ART and Option B+, we believe that in the context of
implementation research, it is not any longer a highly
relevant comparison group. As another limitation, hos-
pital staff often omitted peripartum HIV tests among
presumably seronegative women, and we had to exclude
numerous delivering women due to unconfirmed seros-
tatus. Participants were also excluded due to missing
newborn data. Infants who were stillborn or highly un-
stable after delivery were in some cases not assessed and
weighed. However, the overall sample size is still consid-
ered large enough to provide valid findings with regard
to our study question. We acknowledge that there might
be other co- factors and conditions which were not
assessed in our study, but which may also have played a
role in influencing ABOs, like gestational diabetes or
sexually transmitted infections, and these should be con-
sidered in future studies. Furthermore, we assessed
gestational age with the Finnstroem score method. Finn-
stroem et al. describe a possibility of variation of up to
3 weeks in estimation of the GW through their method
[30], so some misclassification is possible, especially in
the transition zone of pre-term and term delivery. Lastly,
regarding MIP as an important predictor for ABO, retro-
spective self-reported occurrence, timing and frequency
of MIP need to be seen in the light of potential reporting
bias. The same applies for the timing and intake of
ARVs, antimalarial treatment and prophylaxis, as far as
not noted on the ANC cards, as well as for obstetric and
clinical history.
Conclusions
While observed rates for ABOs in our study setting were
overall considerably high, we did not find an adverse ef-
fect on birth outcomes for infants exposed to ARVs in-
cluding both ARTpc and Option B+, independently
from maternal intake duration. This is a promising result
in the light of further roll- out of Option B+ and ART
programmes in Subsaharan-African settings, especially
considering the most recent “test and treat”- approach
intending immediate treatment start for all HIV- in-
fected individuals including pregnant women pursued by
the WHO as well as by the Ugandan Ministry of Health
after 2014 [8, 67]. Some other identified risk factors for
ABOs, like hypertension, anaemia or delayed care caused
by long travel distance might be avoided by improve-
ment of ANC services, including better clinical screen-
ing and triage systems for timely referral. Also, effective
preventive measures against MIP are urgently required
to protect newborns from undesirable birth outcomes.
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